disease 3,237 words KG: ent-dise-c8b0ef01
Contents

DLB, Parkinson's Disease, and Alzheimer's Disease: Cross-Disease Comparison Matrix

Disease Info
DLBAlpha-synuclein is the primary driver. Cortical involvement is early and prominent. Lewy bodies distributed diffusely across cortex and limbic system simultaneously[@mckeith2024].
PDAlpha-synuclein follows a brainstem-to-cortical gradient. Motor symptoms precede cortical involvement by years[@aarsland2021].
ADDistinct dual proteinopathy — amyloid-beta plaques (extracellular) and tau neurofibrillary tangles (intracellular). Amyloid accumulation precedes tau spreading by years.
DLB/AD50-60% of DLB cases have moderate-to-severe AD co-pathology. The presence of amyloid-beta and tau modifies the clinical phenotype and predicts faster decline.
PD/ADMany PD patients develop sufficient amyloid and tau pathology to meet criteria for concomitant AD.
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Related Hypotheses (30)

Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.85
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.85
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.78
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76

Related Analyses (26)

Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived

Related Experiments (30)

Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cholinergic System Dysfunction in DLB — Mechanisms and Thera
clinical · proposed · Score: 0.40
DLB Treatment Response Biomarkers — Predicting Cholinesteras
clinical · proposed · Score: 0.40
Genetic Risk Modifiers in DLB Phenotype
clinical · proposed · Score: 0.40

See Also (15)

GFAP in Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Olfactory Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Alzheimer's Disease Biomarkers
biomarker · Pages share 18 hypotheses
ASL Perfusion Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
biomarker · Pages share 21 hypotheses

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)